HR Execs on the Move

Blue Cross Blue Shield of Kansas City (BCBSKC)

www.bcbskc.com

 
Blue Cross Blue Shield of Kansas City (BCBSKC) is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Blue Cross Blue Shield of Kansas City (BCBSKC) is based in Kansas City, MO. You can find more information on Blue Cross Blue Shield of Kansas City (BCBSKC) at www.bcbskc.com
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Nursing Resources

Nursing Resources is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProMed Molded Products

ProMed Molded Products is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Thermotex Therapy Systems

Thermotex Therapy Systems Ltd. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PAT Services

PAT Services is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.